Trump administration plans new drug-pricing agreements with biotech companies for Medicaid discounts, exempting them from Medicare discounts and offering tariff relief.
Trump administration plans new drug-pricing agreements with biotech companies for Medicaid discounts, exempting them from Medicare discounts and offering tariff relief.